×
About 5,213 results

ALLMedicine™ Ocular Hypertension Center

Research & Reviews  1,390 results

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
https://clinicaltrials.gov/ct2/show/NCT03850782

Jun 24th, 2022 - This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not a...

A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
https://clinicaltrials.gov/ct2/show/NCT05022004

Jun 24th, 2022 - This is a randomized, Investigator-masked, multi-center, parallel group, therapeutic equivalence study with clinical endpoint.

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
https://clinicaltrials.gov/ct2/show/NCT04499248

Jun 21st, 2022 - This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-group (Cohort 2) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension

Selective laser trabeculoplasty for steroid-induced ocular hypertension following endot...
https://doi.org/10.1080/02713683.2022.2088800
Current Eye Research; Davidson M, Berkowitz E et. al.

Jun 11th, 2022 - Purpose: To examine the safety and efficacy of selective laser trabeculoplasty (SLT) in patients responding to topical steroids with elevated intraocular pressure following endothelial keratoplasty.Methods: Patients that underwent Descemet Membran...

see more →

Drugs  163 results see all →

Clinicaltrials.gov  459 results

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
https://clinicaltrials.gov/ct2/show/NCT03850782

Jun 24th, 2022 - This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not a...

A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
https://clinicaltrials.gov/ct2/show/NCT05022004

Jun 24th, 2022 - This is a randomized, Investigator-masked, multi-center, parallel group, therapeutic equivalence study with clinical endpoint.

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
https://clinicaltrials.gov/ct2/show/NCT04499248

Jun 21st, 2022 - This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-group (Cohort 2) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension

Study of LL-BMT1 in Patients With Elevated Intraocular Pressure
https://clinicaltrials.gov/ct2/show/NCT04747808

Jun 8th, 2022 - This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single dose of LL-BMT1.

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
https://clinicaltrials.gov/ct2/show/NCT05401357

Jun 3rd, 2022 - Subjects with chronic open-angle glaucoma or ocular hypertension in both the eyes and meeting all the mentioned inclusion criteria and none of the exclusion criteria will be identified. At baseline (Day 0), subjects qualifying Intra Ocular Pressur...

see more →

News  73 results

Wet Your Whistles: Alcohol-Induced Flushing With Use of Topical Calcineurin Inhibitors
https://www.mdedge.com/dermatology/article/252375/atopic-dermatitis/wet-your-whistles-alcohol-induced-flushing-use-topical
Emily C. Milam, MD, David E. Cohen, MD, MPH

Mar 3rd, 2022 - Practice Gap The topical calcineurin inhibitors (TCIs) tacrolimus and pimecrolimus are US Food and Drug Administration approved for the treatment of atopic dermatitis. 1 In addition, these 2 drugs are utilized off label for many other dermatologic.

Omidenepag Matches Latanoprost for Glaucoma
https://www.medscape.com/viewarticle/962994

Nov 15th, 2021 - NEW ORLEANS, Louisiana — An experimental new drug for glaucoma and ocular hypertension is as effective as latanoprost but causes different adverse events, the results of a phase 3 clinical trial suggest. Approved in Japan in 2018 and under review ...

Treatment Not Always Needed to Prevent Vision Loss From High Eye Pressure
https://www.medscape.com/viewarticle/950011

Apr 28th, 2021 - NEW YORK (Reuters Health) - Not all patients with elevated intraocular pressure (IOP) need pressure-reducing treatment to prevent glaucoma-related vision loss, according to new data from a large twenty-year cohort study. "With only 25% of the indi...

Preservative-Free Tafluprost/Timolol Fixed Combo Reduces IOP in Open-Angle Glaucoma
https://www.medscape.com/viewarticle/946281

Apr 28th, 2021 - Takeaway Preservative-free tafluprost (0.0015%)/timolol (0.5%) fixed combination (PF-Taf-T-FC) was effective in reducing intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT), inadequately controlled on...

Ocular Hypertension Trial Supports Watching and Waiting
https://www.medscape.com/viewarticle/949371

Apr 15th, 2021 - Only about a quarter of patients with ocular hypertension lose peripheral vision, so clinicians should not recommend treatment to everyone with this condition, a long-term study suggests. The 20-year results of the phase 3 Ocular Hypertension Stud...

see more →